Literature DB >> 32029132

Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization.

Connie N Hess1, Tracy Y Wang2, Julia Weleski Fu3, Jacob Gundrum3, Nancy M Allen LaPointe3, R Kevin Rogers4, William R Hiatt5.   

Abstract

BACKGROUND: Long-term cardiovascular and limb outcomes after revascularization for peripheral artery disease and, in particular, prognosis after post-procedure major adverse limb events (MALE) are not well-studied.
OBJECTIVES: This study sought to describe outcomes after peripheral revascularization and assess relationships between post-procedure MALE hospitalization and subsequent events.
METHODS: Patients undergoing peripheral artery revascularization between January 1, 2009, and September 30, 2015, in the Premier Healthcare Database were examined for the co-primary outcomes of interest, composite myocardial infarction (MI) or stroke and composite major amputation or peripheral revascularization. Multivariable adjusted Cox proportional hazards models with post-procedure MALE hospitalization included as a time-dependent covariate were developed to estimate hazard ratios for outcomes.
RESULTS: Among 393,017 revascularized patients followed for a median of 2.7 years (interquartile range: 1.3 to 4.4 years), the cumulative incidence of MI or stroke was 9.8% and that of major amputation or peripheral revascularization was 41.9%. A total of 50,750 patients (12.9%) had at least 1 post-procedure MALE hospitalization. In time-dependent covariate adjusted models, post-procedure MALE hospitalization was associated with greater risk of subsequent MI or stroke (hazard ratio: 1.34; 95% confidence interval: 1.28 to 1.40) and major amputation or peripheral revascularization (hazard ratio: 8.13; 95% confidence interval: 7.96 to 8.29). After peripheral revascularization with or without post-procedure MALE hospitalization, risk of limb events increased rapidly post-procedure and more slowly after the first year, whereas cardiac risk increased steadily during follow-up.
CONCLUSIONS: Revascularized peripheral artery disease patients face earlier limb and later cardiovascular ischemic risk that is heightened among patients with post-procedure MALE hospitalization. Increased provider awareness of these long-term risks may guide efforts to improve post-procedural outcomes.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  outcomes; peripheral artery disease; revascularization

Mesh:

Year:  2020        PMID: 32029132     DOI: 10.1016/j.jacc.2019.11.050

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Mono or Dual Antiplatelet Therapy for Treating Patients with Peripheral Artery Disease after Lower Extremity Revascularization: A Systematic Review and Meta-Analysis.

Authors:  Shang-Yu Tsai; Ying-Sheng Li; Che-Hsiung Lee; Shion-Wei Cha; Yao-Chang Wang; Ta-Wei Su; Sheng-Yueh Yu; Chi-Hsiao Yeh
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-12

2.  Buyang Huanwu Decoction Enhances Revascularization via Akt/GSK3β/NRF2 Pathway in Diabetic Hindlimb Ischemia.

Authors:  Xiao-Yi Bao; Li-Hui Deng; Zi-Jun Huang; Abdirizak S Daror; Zi-Hao Wang; Wang-Jun Jin; Zhuang Zhuang; Qiang Tong; Guo-Qing Zheng; Yan Wang
Journal:  Oxid Med Cell Longev       Date:  2021-12-03       Impact factor: 6.543

3.  Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.

Authors:  Connie N Hess; Michael Szarek; Sonia S Anand; Rupert M Bauersachs; Manesh R Patel; E Sebastian Debus; Mark R Nehler; Warren H Capell; Joshua A Beckman; Gregory Piazza; Stanislav Henkin; Alessandra Bura-Rivière; Holger Lawall; Karel Roztocil; Judith Hsia; Eva Muehlhofer; Scott D Berkowitz; Lloyd P Haskell; Marc P Bonaca
Journal:  JAMA Netw Open       Date:  2022-06-01

4.  Clinical experience with dual pathway inhibition therapy: case series and mini review.

Authors:  Tobias Geisler; Kelley Branch; Sigrid Nikol
Journal:  Eur Heart J Case Rep       Date:  2022-05-19

5.  Clinical Outcomes after Endovascular Revascularisation of the Femoropopliteal Arterial Segment in Patients with Anticoagulant versus Antiplatelet Therapy: A Single-Centre Retrospective Cohort Study.

Authors:  Kevin Pelicon; Klemen Petek; Anja Boc; Vinko Boc; Nataša Kejžar; Tjaša Vižintin Cuderman; Aleš Blinc
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-30

6.  Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.

Authors:  Scott D Berkowitz; Rupert M Bauersachs; Michael Szarek; Mark R Nehler; E Sebastian Debus; Manesh R Patel; Sonia S Anand; Warren H Capell; Connie N Hess; Judy Hsia; Nicholas J Leeper; David Brasil; Lajos Mátyás; Rafael Diaz; Marianne Brodmann; Eva Muehlhofer; Lloyd P Haskell; Marc P Bonaca
Journal:  J Thromb Haemost       Date:  2022-03-07       Impact factor: 16.036

7.  Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England.

Authors:  Laura Portas; Rupert Bauersachs; Kevin Bowrin; Jean-Baptiste Briere; Alexander Cohen; Maria Huelsebeck; Schuyler Jones; Jennifer K Quint
Journal:  Vasc Med       Date:  2022-06-07       Impact factor: 4.739

8.  The impact of chronic kidney disease on outcomes following peripheral vascular intervention.

Authors:  Dennis I Narcisse; Elizabeth Hope Weissler; Jennifer A Rymer; Ehrin J Armstrong; Eric A Secemsky; William A Gray; Jihad A Mustapha; George L Adams; Gary M Ansel; Manesh R Patel; William Schuyler Jones
Journal:  Clin Cardiol       Date:  2020-08-11       Impact factor: 2.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.